Jiangsu HengRui Medicine Co., Ltd. Drug Pipeline

Jiangsu HengRui Medicine Co., Ltd. maintains a substantial clinical development portfolio, with 401 trials registered since 2008, and 103 currently active programs. The pipeline spans from Phase 1 through Phase 4, with a distribution of 41, 51, 34, and 1 active trials respectively. Development activity covers 14 therapeutic areas, but is heavily concentrated in oncology, which accounts for 66% of active programs (68 trials). Within oncology, the leading indications by active trial count are solid tumor (advanced) with 22 active trials, prostate cancer with 11 active trials including 3 in Phase 3, and breast cancer with 9 active trials including 5 in Phase 3. Other therapeutic areas with active trials include metabolic diseases (8 active trials), rare diseases (3 active trials), musculoskeletal disorders (2 active trials), respiratory diseases (2 active trials), and dermatology (2 active trials). The significant number of Phase 3 trials in oncology, particularly in prostate and breast cancer, suggests a potential for near-term catalysts within that therapeutic area.